PATENT CLAIM ANALYSIS

Application Number: 15760775
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["514", "969000"]

Abstract:
This invention provides ex vivo methods for making modified PBMC compositions having overall anti-fugetactic properties for the effective and efficient treatment of tumors or cancers in a patient, and compositions and use thereof, following treatment with an antigen presenting cell-based vaccine against a cancer antigen.

Claim (Index 12):
The immune cell composition of  claim 11 , wherein the fusion protein comprises a tumor antigen portion and an immune signaling factor portion.

Metadata:
- Claim Count in Document: 28.0
- Percentile: 90.0
- Lexical Diversity: 1.2
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15840930', '11667410', '10191988', '10143553', '10222960']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7667118349622665
- 35 USC 102 Novelty (BERT): 0.5170526821928273
- Combined Prediction Score: 0.7417459196853227
- Mean Citation Score: 261.28957599999995
- Max Citation Score: 282.5945
- Similarity Product: 181.49518948495387

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test